Phase 4 N=113 Buprenorphine Maintenance vs. Detoxification in Prescription Opioid Dependence
Opiate Dependence
Primary: Illicit Opioid Use — 35.2; 53.2 percent of opioid negative urine samples
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=175 RCT Comparing Methadone and Buprenorphine in Pregnant Women
Opioid Related Disorders · Pregnancy · Opioid Dependence
Primary: Child's Head Circumference Measurement (Measured at Birth) — 33.0; 33.8 cm
Phase 4 N=54 Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients
Opiate Addiction
Primary: Number of Participants Retained in Treatment — 13; 13 participants — p=0.77
Phase 4 N=19 Buprenorphine and Methadone for Opioid-dependent Chronic Back Pain Patients
Low Back Pain
Primary: Analgesia — 36.3; 71.8 units on a VAS scale — p=0.097
Phase 3 N=9 Buprenorphine Treatment for Opioid Dependence
Opioid Dependence
Primary: Urine Toxicology for Opiate Use — 2; 4; 2; 0 Participants
Phase 2 N=12 A Within Subject Comparison of Opioid Withdrawal in Opioid Dependent Individuals
Opioid Abuse · Opioid Dependence
Primary: Mean Peak Opioid Withdrawal Assessed by the Clinical Opiate Withdrawal Scale (COWS) — 12.6; 1.3 units on a scale
Phase 1 N=34 Drug Interaction Study With BI 201335 and Methadone or Buprenorphine/Naloxone
Hepatitis C
Primary: R-methadone: Geometric Mean Steady-state AUC0-24 on Day 1 and on Day 9. — 6990; 5920 [ng*h/mL] — p=0.1638
Phase 3 N=30 Buprenorphine/Naloxone Stabilization and Induction Onto Injection Naltrexone
Opioid Dependence
Primary: Successful Induction Onto XR-NTX — 8 Participants
Phase 2 N=6 Nalrexone Facilitated Discontinuation of Buprenorphine
Stable Opioid Dependence
Primary: Successful Discontinuation of Buprenorphine — 6 Participants
Phase 4 N=1,269 Starting Treatment With Agonist Replacement Therapies (START)
Opiate-related Disorders
Primary: Hepatic Safety — 278; 318; 41; 62 participants — p=< 0.05
Phase 2 N=25 Improving Buprenorphine Detoxification Outcomes With Isradipine
Opioid Dependence
Primary: Change Over Time in Illicit Opioid Use Via Urine Toxicology Screens During Buprenorphine Taper (Wks 5-6) — -1.25; -0.36 opioid-positive urine — p=.42
Phase 4 N=15 Buprenorphine Loading in the Emergency Department
Opioid-use Disorder
Primary: Number of Participants With Successful Rapid Induction — 14 Participants
Phase 2 N=30 Effects of Gabapentin Versus Placebo on Buprenorphine Detoxification of Opioid-dependent Individuals
Opioid Dependence · Opioid Withdrawal · Opioid Detoxification
Primary: Illicit Opioid Use as Determine by Urine Dipsticks — 13.64; 32.56 % of urines positive for opioids — p=0.035
Phase 1 N=21 A Study to Evaluate the Pharmacokinetic Effect of SCH 503034 (Boceprevir) on Methadone or Buprenorphine/Naloxone Plasma Concentrations (P08123)
Hepatitis C Virus
Primary: Area Under the Concentration Versus Time Curve (AUC) at Steady State of Methadone Enantiomers When Administered With or Without Boceprevir — 50.1; 42.4; 56.9; 44.6…
Phase 3 N=20 Buprenorphine Maintenance Treatment of Opioid Dependence in Primary Care: A Randomized Clinical Trial
Opioid-Related Disorders · Heroin Dependence
Primary: The Primary Outcome Will Include a Comparison of the Proportion of Patients Successfully Inducted One Week After the Initial Primary Care Visit. — 6; 6 participants
Phase 4 N=16 Evaluating the Safety of Acute Baclofen in Methadone-maintained Individuals With Opiate Dependence.
Addiction Opiate
Primary: Number of Participants With Dose Limiting Toxicities — 0; 0; 0; 0 participants
Phase 4 N=60 Preference for Subutex® (Buprenorphine) Versus Suboxone® (Buprenorphine/Naloxone) in Opioid Dependent Patients on Subutex® (Study P05094)(COMPLETED)
Opiate-related Disorders · Opiate Dependence · Drug Abuse
Primary: Subject's Self Assessment Using 10 cm Visual Analogue Scale (VAS) of Overall Preference for One of the Two Buprenorphine-based Maintenance Therapies (Suboxone® or…
N/A N=104 Start Treatment and Recovery for Opioid Use Disorder
Opioid-use Disorder · Mental Disorder · Opioid Medication Assisted Treatment
Primary: Number of Participants With Self-reported Treatment Retention — 51 Participants
Phase 2 N=38 Induction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/Naloxone
Opioid-related Disorders
Primary: Severity of Withdrawal Symptoms Measured Using the Clinical Opiate Withdrawal Scale (COWS) at Baseline and the Peak COWS up to 23.5 Hours After the First Administration…
Phase 3 N=11 A Strategy to Improve Success of Treatment Discontinuation in Buprenorphine Responders
Opioid-use Disorder
Primary: Percent of Patients Successfully Transitioned Off Buprenorphine — 2; 3 Participants
Phase 4 N=28 Morphine Versus Methadone for Opiate Exposed Infants With Neonatal Abstinence Syndrome
Neonatal Abstinence Syndrome
Primary: Length of Hospital Stay — 17.9; 16.1 days
Phase 4 N=31 Comparison Between Methadone and Morphine for Neonatal Opiate Withdrawal
Neonatal Abstinence Syndrome
Primary: Days of Treatment With Opioid Medication — 13.9; 22.9 days
N/A N=375 Contingency Management to Enhance Office-Based Buprenorphine Treatment
Opioid-use Disorder
Primary: Buprenorphine Adherence as Assessed by the Percentage of Buprenorphine-positive Urine Samples — 80; 84; 78 percentage of urine samples — p==0.22
Phase 2 N=4 Benzodiazepine Discontinuation in Opioid Agonist Therapy
Substance Use Disorders
Primary: Participant Acceptability of the Interventions — 1; 0 Participants
Phase 3 N=63 Blinded Trial of Buprenorphine or Morphine in the Treatment of the Neonatal Abstinence Syndrome
Neonatal Abstinence Syndrome
Primary: Length of Treatment — 15; 28 days — p=<0.05
Phase 2 N=10 Buprenorphine Pharmacometric Open Label Research Study of Drug Exposure
Neonatal Abstinence Syndrome · Neonatal Opiate Withdrawal Syndrome
Primary: Buprenorphine Pharmacokinetics
Phase 3 N=87 Memantine-enhanced Buprenorphine Treatment for Opioid-dependent Young Adults
Opioid Dependence
Primary: Change of Opioid Use From Week 1 to 13 — 0.00; 0.27; 0.39 Mean Proportion of Opioid Use in Week 13 — p==0.00874
Phase 4 N=188 A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users (P05042)(COMPLETED)
Opiate Dependence · Drug Dependence · Substance Dependence
Primary: Responders at Day 3 — 85; 85; 8; 9 Participants
Phase 4 N=281 Buprenorphine to Improve HIV Care Engagement and Outcomes
HIV · Substance Related Disorders
Primary: Number of Participants With HIV Viral Suppression — 97; 92; 74; 99 Participants
Phase 2 N=103 Medications Development for Drug Abuse Disorders
Opioid Related Disorders · Opioid Dependence · Opioid Addiction
Primary: Mean Ratings on Clinical Opiate Withdrawal Scale (COWS) Measure of Withdrawal During Double-blind Taper (7-days) and Post-taper (7-days) Period. — 7.79; 8.41; 8.28; 6.16…